YOLFTbeta
47

Mycenax Biotech

4726 · TWO · Healthcare / Biotechnology

22.45TWD+0.10 (+0.45%)

Price History

Full chart

Market Stats

Previous Close22.35
Open22.70
Day Range22.15 – 22.75
52-Week Range22.10 – 37.60
Volume107.41K
Market Cap4.80B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.85
Dividend Yield0.00%
Beta0.45
50-Day Avg23.83
200-Day Avg28.41

About

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Pei-Jiun Chen Ph.D.
  • Employees0
  • HeadquartersNo. 66, Shengyi 2nd Rd., Zhubei, Taiwan, 302041, Taiwan
  • Websitehttps://www.mycenax.com

Leadership

  • Ms. Pei-Jiun Chen Ph.D.President CEO & Chairman
  • Ms. Liru YehAssistant Vice President of Finance & Accounting Division

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue318.64M211.42M390.84M665.34M774.27M732.28M652.62M683.92M740.24M
Growth (%)--33.65%+84.86%+70.23%+16.37%-5.42%-10.88%+4.80%+8.23%
Cost of Revenue178.83M197.32M258.34M478.81M636.66M845.95M1.03B925.28M921.65M
Gross Profit139.81M14.11M132.51M186.53M137.61M-113.67M-375.19M-241.36M-181.41M
Gross Margin43.88%6.67%33.90%28.04%17.77%-15.52%-57.49%-35.29%-24.51%
Operating Expense261.28M334.96M361.71M140.27M230.10M300.17M228.04M220.13M223.98M
Operating Income-121.47M-320.85M-229.20M46.27M-92.49M-413.84M-603.23M-461.48M-405.39M
Operating Margin-38.12%-151.76%-58.64%6.95%-11.95%-56.51%-92.43%-67.48%-54.76%
EBITDA-58.00M-205.54M-104.76M166.03M82.83M-161.09M-341.95M-136.46M-136.11M
EBITDA Margin-18.20%-97.22%-26.80%24.95%10.70%-22.00%-52.40%-19.95%-18.39%
Net Income-188.37M-274.43M-218.18M30.95M-89.86M-453.63M-682.85M-467.13M-448.63M
Net Income Margin-59.12%-129.80%-55.82%4.65%-11.61%-61.95%-104.63%-68.30%-60.61%
R&D195.47M276.09M284.57M46.50M96.13M144.00M75.81M78.19M75.91M
R&D as % of Total Revenue61.35%130.58%72.81%6.99%12.42%19.66%11.62%11.43%10.25%
Interest Expense0296.00K1.92M865.00K2.53M19.19M27.25M29.92M33.67M
Interest Expense % of Total Revenue0.00%0.14%0.49%0.13%0.33%2.62%4.17%4.37%4.55%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.31B1.12B1.41B1.75B3.14B4.45B3.77B3.37B3.26B
Total Liabilities168.93M211.70M306.04M540.89M1.23B1.35B1.32B1.34B1.66B
Total Equity1.14B907.01M1.10B1.21B1.91B3.11B2.45B2.02B1.60B
Cash342.06M215.75M193.67M291.14M286.93M1.32B519.27M269.56M224.54M
Net Debt----237.47M-137.05M509.88M685.68M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-45.55M-180.27M-140.74M174.17M-146.23M-150.19M-131.18M-191.68M-27.24M
Investing Cash Flow75.82M53.95M-266.19M-168.58M-1.03B-745.24M---
Financing Cash Flow2.02M384.86M384.86M91.88M1.17B1.93B---
Capital Expenditure91.51M118.48M177.91M260.22M1.10B626.94M297.60M330.51M99.08M
Free Cash Flow-137.40M-301.08M-319.55M-88.09M-1.26B-789.16M-428.78M-522.19M-126.32M
FCF to OCF301.65%167.02%227.05%-50.58%861.16%525.46%326.87%272.43%463.71%

Earnings

Report DateMar 31, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 14, 2014Aug 12, 2014Nov 11, 2014Mar 23, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 16, 2016Nov 11, 2016Mar 2, 2017May 13, 2017Aug 11, 2017Nov 14, 2017Mar 30, 2018May 11, 2018Aug 13, 2018Nov 12, 2018Feb 27, 2019May 13, 2019Aug 14, 2019Nov 12, 2019Mar 20, 2020May 12, 2020Aug 12, 2020Nov 12, 2020Mar 30, 2021May 13, 2021Aug 10, 2021Nov 9, 2021Mar 11, 2022May 10, 2022Aug 10, 2022Nov 11, 2022Mar 13, 2023May 10, 2023Aug 10, 2023Nov 13, 2023Mar 13, 2024
EPS Estimate-----0.26-0.04-0.16-0.15---------------------0.290.790.190.65-------0.44-0.50--0.31-0.18-
EPS Actual-0.39-0.18-0.30-0.09-0.40-0.06-0.35-0.06-0.33-0.48-0.04-0.15-0.55-0.48-0.21-0.21-0.66-0.210.20-1.04-0.64-0.51-0.51-0.84-0.44-0.24-0.73-0.33-0.170.62-0.11-0.100.85-0.45-0.52-0.370.12-0.76-1.12-0.98-1.17-0.82-0.59-0.74
Surprise-----53.85%-50.00%-118.75%60.00%--------------------41.38%-21.52%-157.89%-115.38%-------154.55%-96.00%--164.52%-227.78%-
Timing----Pre-market-Pre-marketAfter-hours-----Pre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-market-After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap4.80B
Enterprise Value5.49B
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.89
Price / Book3.29
EPS-1.85
Book Value6.80
Revenue (TTM)815.87M
Gross Profit (TTM)-137.68M
EBITDA-96.67M
Profit Margin-46.81%
Operating Margin-34.32%
Return on Equity-24.06%
Return on Assets-6.86%
Shares Outstanding207.04M
Shares Float112.98M
Beta0.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%